Aldosterone News and Research

RSS

Aldosterone is a steroid hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps control the balance of water and salts in the kidney by keeping sodium in and releasing potassium from the body. Too much aldosterone can cause high blood pressure and a build-up of fluid in body tissues. Aldosterone is a type of mineralocorticoid hormone.

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

17 Nov 2012

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

3 Nov 2012

Researchers discover genetic biomarker for age-related hearing loss

University of South Florida researchers have identified a genetic biomarker for age-related hearing loss, a major breakthrough in understanding and preventing a condition of aging that affects 30 million Americans and greatly diminishes their quality of life.

26 Oct 2012

Older adults do not tend to adhere to their prescribed drugs after heart attack

Older adults who have had a heart attack don't tend to adhere to their prescribed drugs according to a new study of Medicare beneficiaries by the University of Maryland School of Pharmacy.

11 Oct 2012

Sleep apnea’s contribution to diabetic nephropathy needs attention

The effect of obstructive sleep apnea syndrome on the development of diabetic nephropathy requires investigation, say researchers.

31 Aug 2012

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

27 Aug 2012

Pendrin a possible new target for diuretic therapy

In patients with fluid overload, inhibition of the chloride-absorbing transporter pendrin and the NaCl co-transporter may provide an effective diuretic regimen without triggering hypokalemia, research suggests.

6 Aug 2012

First clinical trial to test cardiac drug regimen for DMD

The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease.

27 Jun 2012

Aldosteronism linked to poor bone health

Primary aldosteronism is associated with low bone mass, increased prevalence of osteoporosis, and vertebral fractures, Italian research shows.

7 Jun 2012

Too much salt and aldosterone leads to high blood pressure, tissue damage

Nearly 40 percent of the small adrenal tumors that cause big problems with high blood pressure share a genetic mutation that causes patients to retain too much sodium, researchers report.

31 May 2012

No added benefit of aliskiren-amlodipine fixed drug combination for hypertension

The fixed drug combination of aliskiren and amlodipine (trade name: Rasilamlo-) was approved in April 2011 for the treatment of people with hypertension in whom aliskiren or amlodipine alone has an insufficient effect.

23 Mar 2012

Combination of key guideline-recommended heart failure therapies improve survival odds

A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvement of up to 90 percent in the odds of survival over two years.

22 Feb 2012

Medtronic begins two Symplicity renal denervation system clinical initiatives

Medtronic, Inc. announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company's Symplicity renal denervation system across multiple conditions.

From Medtronic 13 Feb 2012

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Blocking CaM kinase may help prevent cardiac rupture

For people who initially survive a heart attack, a significant cause of death in the next few days is cardiac rupture -- literally, bursting of the heart wall. A new study by University of Iowa researchers pinpoints a single protein as the key player in the biochemical cascade that leads to cardiac rupture.

18 Nov 2011

Salt – is it bad for the heart? Debate continues

Salt or high sodium intake in diet has drawn attention of researchers for a while now. The U.S. Food and Drug Administration held a day-long hearing today, discussing strategies to help Americans cut the salt from their diets as a latest attempt to curb sodium in the American diet.

13 Nov 2011

New insights into nephrotic syndrome and high blood pressure

Scientists have now begun to understand kidney damage on a cellular level and how the activity of certain molecules in damaged kidneys contributes to salt and water retention in nephrotic syndrome.

23 Sep 2011

U-M Professor to review data from three prominent studies on heart failure

Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists.

20 Sep 2011